| Home | E-Submission | Sitemap | Editorial Office |  
top_img
Cancer Research and Treatment Search > Browse Articles > Search



Lung and Thoracic cancer
EGFR-TKI Combined with Pemetrexed versus EGFR-TKI Monotherapy in Advanced EGFR-Mutated NSCLC: A Prospective, Randomized, Exploratory Study
Weiguang Gu, Hua Zhang, Yiyu Lu, Minjing Li, Shuang Yang, Jianmiao Liang, Zhijian Ye, Zhihua Li, Minhong He, Xiaoliang Shi, Fei Wang, Dong You, Weiquan Gu, Weineng Feng
Cancer Res Treat. 2023;55(3):841-850.   Published online February 13, 2023    DOI: https://doi.org/10.4143/crt.2022.1438
                        Supplementary      
EGFR Mutation–Positive Unresectable Stage III Non-Squamous Lung Cancer Is Associated with a High Incidence of Brain Metastasis
Hongsik Kim, Sehhoon Park, Hyun Ae Jung, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Myung-Ju Ahn
Cancer Res Treat. 2023;55(2):498-505.   Published online October 4, 2022    DOI: https://doi.org/10.4143/crt.2022.388
                           Cited By 1
Osimertinib Combined with Systemic Chemotherapy for EGFR Mutant, T790M-Negative, Non–Small Cell Lung Cancer Patients Who Develop Leptomeningeal Metastases with Extracranial Progression to Prior EGFR TKI
Hye Ryeon Kim, Hyunji Jo, Hongsik Kim, Joohyun Hong, Sehhoon Park, Hyun Ae Jung, Se-Hoon Lee, Jin-Seok Ahn, Myung-Ju Ahn
Cancer Res Treat. 2023;55(1):344-349.   Published online March 26, 2022    DOI: https://doi.org/10.4143/crt.2021.1603
                           Cited By 1
Lung and Thoracic cancer
Real-World Study of Osimertinib in Korean Patients with Epidermal Growth Factor Receptor T790M Mutation–Positive Non–Small Cell Lung Cancer
Jang Ho Lee, Eun Young Kim, Cheol-Kyu Park, Shin Yup Lee, Min ki Lee, Seong-Hoon Yoon, Jeong Eun Lee, Sang Hoon Lee, Seung Joon Kim, Sung Yong Lee, Jun Hyeok Lim, Tae-Won Jang, Seung Hun Jang, Kye Young Lee, Seung Hyeun Lee, Sei Hoon Yang, Dong Won Park, Chan Kwon Park, Hye Seon Kang, Chang Dong Yeo, Chang-Min Choi, Jae Cheol Lee
Cancer Res Treat. 2023;55(1):112-122.   Published online July 19, 2022    DOI: https://doi.org/10.4143/crt.2022.381
                        Supplementary         Cited By 1
Breast cancer
Clinical Significance of Major Angiogenesis-Related Effectors in Patients with Metastatic Breast Cancer Treated with Trastuzumab-Based Regimens
Helen P. Kourea, Foteinos-Ioannis Dimitrakopoulos, Georgia-Angeliki Koliou, Anna Batistatou, Kyriaki Papadopoulou, Mattheos Bobos, Anthoula Asimaki-Vlachopoulou, Sofia Chrisafi, Kitty Pavlakis, Kyriakos Chatzopoulos, Eleni Galani, George Pentheroudakis, Dimitrios Pectasides, Dimitrios Bafaloukos, Eleni Res, Pavlos Papakostas, Angelos Koutras, Vassiliki Kotoula, George Fountzilas
Cancer Res Treat. 2022;54(4):1053-1064.   Published online November 17, 2021    DOI: https://doi.org/10.4143/crt.2021.748
                        Supplementary      
Lung and Thoracic cancer
The Impact of EGFR Tyrosine Kinase Inhibitor on the Natural Course of Concurrent Subsolid Nodules in Patients with Non–Small Cell Lung Cancer
Noeul Kang, Ki Hwan Kim, Byeong-Ho Jeong, Kyungjong Lee, Hojoong Kim, O Jung Kwon, Myung-Ju Ahn, Jeonghee Cho, Ho Yun Lee, Sang-Won Um
Cancer Res Treat. 2022;54(3):817-826.   Published online November 9, 2021    DOI: https://doi.org/10.4143/crt.2021.822
                        Supplementary         Cited By 2
Acquired Resistance Mechanism of EGFR Kinase Domain Duplication to EGFR TKIs in Non–Small Cell Lung Cancer
Chaelin Lee, Miso Kim, Dong-Wan Kim, Tae Min Kim, Soyeon Kim, Sun-Wha Im, Yoon Kyung Jeon, Bhumsuk Keam, Ja-Lok Ku, Dae Seog Heo
Cancer Res Treat. 2022;54(1):140-149.   Published online May 3, 2021    DOI: https://doi.org/10.4143/crt.2021.385
                        Supplementary         Cited By 2
Lung cancer
A Phase II Trial of Osimertinib as the First-Line Treatment of Non–Small Cell Lung Cancer Harboring Activating EGFR Mutations in Circulating Tumor DNA: LiquidLung-O-Cohort 1
Cheol-Kyu Park, Hyun-Ju Cho, Yoo-Duk Choi, In-Jae Oh, Young-Chul Kim
Cancer Res Treat. 2021;53(1):93-103.   Published online September 21, 2020    DOI: https://doi.org/10.4143/crt.2020.459
                        Supplementary         Cited By 2
EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation
Sehhoon Park, Bo Mi Ku, Hyun Ae Jung, Jong-Mu Sun, Jin Seok Ahn, Se-Hoon Lee, Keunchil Park, Myung-Ju Ahn
Cancer Res Treat. 2020;52(4):1288-1290.   Published online June 22, 2020    DOI: https://doi.org/10.4143/crt.2020.278
                           Cited By 5
Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in Korea
Seonggyu Byeon, Youjin Kim, Sung Won Lim, Jang Ho Cho, Sehoon Park, Jiyun Lee, Jong-Mu Sun, Yoon-La Choi, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn
Cancer Res Treat. 2019;51(2):623-631.   Published online July 23, 2018    DOI: https://doi.org/10.4143/crt.2018.151
                        Supplementary         Cited By 33
EGFR Mutation Is Associated with Short Progression-Free Survival in Patients with Stage III Non-squamous Cell Lung Cancer Treated with Concurrent Chemoradiotherapy
Song Ee Park, Jae Myoung Noh, You Jin Kim, Han Sang Lee, Jang Ho Cho, Sung Won Lim, Yong Chan Ahn, Hongryull Pyo, Yoon-La Choi, Joungho Han, Jong-Mu Sun, Se Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn
Cancer Res Treat. 2019;51(2):493-501.   Published online June 18, 2018    DOI: https://doi.org/10.4143/crt.2018.125
                           Cited By 23
Phase 1 Studies of Poziotinib, an Irreversible Pan-HER Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors
Tae Min Kim, Keun-Wook Lee, Do-Youn Oh, Jong-Seok Lee, Seock-Ah Im, Dong-Wan Kim, Sae-Won Han, Yu Jung Kim, Tae-You Kim, Jee Hyun Kim, Hyesun Han, Woo Ho Kim, Yung-Jue Bang
Cancer Res Treat. 2018;50(3):835-842.   Published online August 29, 2017    DOI: https://doi.org/10.4143/crt.2017.303
                        Supplementary         Cited By 53
Randomized Phase II Study of Afatinib Plus Simvastatin Versus Afatinib Alone in Previously Treated Patients with Advanced Nonadenocarcinomatous Non-small Cell Lung Cancer
Youngjoo Lee, Ki Hyeong Lee, Geon Kook Lee, Soo-Hyun Lee, Kun Young Lim, Jungnam Joo, Yun Jung Go, Jin Soo Lee, Ji-Youn Han
Cancer Res Treat. 2017;49(4):1001-1011.   Published online January 13, 2017    DOI: https://doi.org/10.4143/crt.2016.546
                           Cited By 29
Incorporating Erlotinib or Irinotecan Plus Cisplatin into Chemoradiotherapy for Stage III Non-small Cell Lung Cancer According to EGFR Mutation Status
Youngjoo Lee, Ji-Youn Han, Sung Ho Moon, Byung-Ho Nam, Kun Young Lim, Geon Kook Lee, Heung Tae Kim, Tak Yun, Hye Jin An, Jin Soo Lee
Cancer Res Treat. 2017;49(4):981-989.   Published online January 6, 2017    DOI: https://doi.org/10.4143/crt.2016.522
                        Supplementary         Cited By 11
Clinical Characteristics and Continued Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Administration in EGFR-mutated Non-Small Cell Lung Cancer with Skeletal Metastasis
Sook-Hee Hong, Yeon-Sil Kim, Ji Eun Lee, In-ho Kim, Seung Joon Kim, Daehee Han, Ie Ryung Yoo, Yang-Guk Chung, Young-Hoon Kim, Kyo-Young Lee, Jin-Hyoung Kang
Cancer Res Treat. 2016;48(3):1110-1119.   Published online January 6, 2016    DOI: https://doi.org/10.4143/crt.2015.289
                           Cited By 7
Antitumor Activity of HM781-36B, alone or in Combination with Chemotherapeutic Agents, in Colorectal Cancer Cells
Mi Hyun Kang, Sung Ung Moon, Ji Hea Sung, Jin Won Kim, Keun Wook Lee, Hye Seung Lee, Jong Seok Lee, Jee Hyun Kim
Cancer Res Treat. 2016;48(1):355-364.   Published online March 5, 2015    DOI: https://doi.org/10.4143/crt.2014.260
                           Cited By 7
How Molecular Understanding Affects to Prescribing Patterns and Clinical Outcome of Gefitinib in Non-small Cell Lung Cancer? 10 Year Experience of Single Institution
Bhumsuk Keam, Dong-Wan Kim, Jin Hyun Park, Jeong-Ok Lee, Tae Min Kim, Se-Hoon Lee, Doo Hyun Chung, Dae Seog Heo
Cancer Res Treat. 2013;45(3):178-185.   Published online September 30, 2013    DOI: https://doi.org/10.4143/crt.2013.45.3.178
                           Cited By 9
Treatment of Non-small Cell Lung Carcinoma after Failure of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
Jae Cheol Lee, Seung Hun Jang, Kye Young Lee, Young-Chul Kim
Cancer Res Treat. 2013;45(2):79-85.   Published online June 30, 2013    DOI: https://doi.org/10.4143/crt.2013.45.2.79
                           Cited By 14
Impact of KRAS Mutation Status on Outcomes in Metastatic Colon Cancer Patients without Anti-Epidermal Growth Factor Receptor Therapy
Seung Tae Kim, Kyong Hwa Park, Jun Suk Kim, Sang Won Shin, Yeul Hong Kim
Cancer Res Treat. 2013;45(1):55-62.   Published online March 31, 2013    DOI: https://doi.org/10.4143/crt.2013.45.1.55
                           Cited By 12
Prognostic Significance of Immunohistochemical Expression of EGFR and C-erbB-2 Oncoprotein in Curatively Resected Gastric Cancer
Hong Suk Song, Young Rok Do, In Ho Kim, Soo Sang Sohn, Kun Young Kwon
Cancer Res Treat. 2004;36(4):240-245.   Published online August 31, 2004    DOI: https://doi.org/10.4143/crt.2004.36.4.240
                           Cited By 18
Expression of EGF Receptor Family Genes and Proteins in Gastric Cacner ( EGFR , c-erbB-2 , c-erbB-3 , c-erbB-4 )
Hae Wan Lee, Eun Young Choi, Chang Dae Bae, Han Kwang Yang, Woo Ho Kim, Jin Pok Kim
J Korean Cancer Assoc. 1998;30(5):853-868.
      
The Prognostic Value of Epidermal Growth Factor Receptor in Primary Breast Cancer
Bong Geun Park, Sung Jae Cha, Sung Joon Park
J Korean Cancer Assoc. 1998;30(4):711-718.
      
Value of Phospholipase C gamma-1, Epidermal Growth Factor Receptor, and Her-2/neu in Human Breast Cancer
Ki Hoon Jung, Sung Han Bae, Eun Sook Lee, Jeoung Won Bae, Bum Whan Koo, In Sun Kim, Cheung Wung Whang
J Korean Cancer Assoc. 1997;29(5):724-737.
      
Expression of Epidermal Growht Factor Receptor mRNA by In Situ Hybridization in Breast Cancer
Won Jong Lee, Soo Jung Lee, Dong Sug Kim, Koing Bo Kwun, Min Chul Chim
J Korean Cancer Assoc. 1996;28(6):996-1010.
      
Expression of Proliferating Cell Nuclear Antigen and Epidermal Growth Factor Receptor in Colorectal carcinomas : Relation of Clinical and Patho
Young Chae Chu, Joon Mee Kim, Young Sik Kim, Young Bae Kim, Tae Sook Hwang
J Korean Cancer Assoc. 1996;28(3):432-443.
      
Immunohisochemical study on the Role of TGF-α / EGFR Autocrine Loop in the Cellular Proliferation and Progression of Gastric Adenocarcinoma
Seong Heum Park, Sung Ock Suh, Young Jae Mok
J Korean Cancer Assoc. 1995;27(5):746-761.
      
The Expression of c-erbB-2 Oncoprotein and Epidermal Growth Factor Receptor ( EGFR ) in Breast Cancer Patients in Korea
Won Park, Nam Sun Paik, Yong Kyu Kim, Nan Mo Moon, Jong Inn Lee, Dong Wook Choi, Dae Yong Hwang, Ja June Jang
J Korean Cancer Assoc. 1994;26(6):901-912.
      
Expression of Epidermal Growth Fasctor Receptor in Breast Cancer Detected by Immunothistochemical Stain in Breast Cancer
Yong Sung Won, Nam Il Kim, Jung Soo Kim, Hae Myung Jeon, Eung Kook Kim, Jae Kwang Kim
J Korean Cancer Assoc. 1994;26(4):567-576.
      
Clinical Validation of the Unparalleled Sensitivity of the Novel Allele-Discriminating Priming System Technology-Based EGFR Mutation Assay in Patients with Operable Non–Small Cell Lung Cancer
Il-Hyun Park, Dae-Soon Son, Yoon-La Choi, Ji-Hyeon Choi, Ji-Eun Park, Yeong Jeong Jeon, Minseob Cho, Hong Kwan Kim, Yong Soo Choi, Young Mog Shim, Jung Hee Kang, Suzy Park, Jinseon Lee, Sung-Hyun Kim, Byung-Chul Lee, Jhingook Kim
Received February 23, 2023   Accepted June 16, 2023   Published online June 20, 2023
DOI: https://doi.org/10.4143/crt.2023.408    
[Epub ahead of print]
                        Supplementary      
Tissue and Plasma-Based Highly Sensitive Blocker Displacement Amplicon Nanopore Sequencing for EGFR Mutations in Lung Cancer
Patinya Akkhasutthikun, Pornchai Kaewsapsak, Pattaraporn Nimsamer, Pavit Klomkliew, Suthida Visedthorn, Pragwalai Chanchaem, Chinachote Teerapakpinyo, Sunchai Payungporn, Sutima Luangdilok
Received July 25, 2023   Accepted November 20, 2023   Published online November 20, 2023
DOI: https://doi.org/10.4143/crt.2023.1108    
[Accepted]
      
Korean Cancer Association
E-Submission
EndNote Output Style
Email Alert
Journal Impact Factor 4.6
SCImago Journal & Country Rank
PubMed Central
MEDLINE/PubMed
Scopus
KoreaMed
KoMCI
ScienceCentral
GoogleScholar
Similarity Check
Crossref Cited-by Linking
CrossMark
Funder Registry
Metadata
ORCID
COPE
Editorial Office
Korean Cancer Association
Room 1824, Gwanghwamun Officia
92 Saemunan-ro, Jongno-gu, Seoul 03186, Korea
TEL: +82-2-3276-2410   FAX: +82-2-792-1410   E-mail: journal@cancer.or.kr
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © Korean Cancer Association.                 Developed in M2PI